Literature DB >> 3510842

Defects in prostaglandin synthesis and metabolism in ulcer disease.

J R Malagelada, D A Ahlquist, S C Moore.   

Abstract

Ulcers occur because of an imbalance between mucosal protective resistance and damaging luminal factors, allowing the latter to predominate. The primary injurious elements are acid and peptic activity. Bile reflux, drugs, and gastroduodenal stasis may alter the luminal milieu and act together with acid-peptic activity to produce injury, weaken mucosal resistance, or both. Since prostaglandins modulate several key mucosal protective mechanisms, and since some exogenous prostaglandins and their derivatives accelerate peptic ulcer healing, it seems plausible that prostaglandin deficiency may contribute to the development of peptic ulcers. At the present time, however, evidence for this postulate is mostly indirect and can be summarized as follows: (1) Defects of mucosal protective mechanisms modulated by prostaglandins have been found in different forms of ulcer disease. Such defects include impaired duodenal bicarbonate secretion, deficient secretion or accelerated degradation of mucus, and reduced mucosal cell proliferation. (2) Drugs that inhibit cyclooxygenase, the key enzyme in tissue prostaglandin synthesis, have ulcerogenic activity. Presumably, in this situation, reduced prostaglandin production renders the mucosa more vulnerable to the action of acid and pepsin, or reduces the capability of the mucosa to repair itself. (3) Decreased mucosal prostaglandin synthesis or prostaglandin content has been found in patients with ulcer disease. Several studies have provided quantitative evidence of disturbed prostaglandin metabolism in some forms of ulcer disease. These studies are of high interest, but they need to be interpreted with caution given the present scientific debate regarding the physiological role of different prostanoids, as well as uncertainty as to the specific cellular source of prostaglandins in gastroduodenal mucosa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510842     DOI: 10.1007/bf01309318

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

Review 1.  Pathogenesis of duodenal ulcer disease.

Authors:  S Szabo
Journal:  Lab Invest       Date:  1984-08       Impact factor: 5.662

2.  Gastric epithelial cell turnover, mucus production, and healing of gastric ulcers with carbenoxolone.

Authors:  W Domschke; S Domschke; J Hagel; L Demling; D N Croft
Journal:  Gut       Date:  1977-10       Impact factor: 23.059

3.  Dietary menhaden oil lowers plasma prostaglandins and calcium in mice bearing the prostaglandin-producing HSDM1 fibrosarcoma.

Authors:  A H Tashjian; E F Voelkel; D R Robinson; L Levine
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

4.  Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils.

Authors:  T H Lee; J M Mencia-Huerta; C Shih; E J Corey; R A Lewis; K F Austen
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

5.  Effect of indomethacin on basal and histamine stimulated human gastric acid secretion.

Authors:  R A Levine; E H Schwartzel
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

6.  A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs.

Authors:  B J Whittle; J R Vane
Journal:  Arch Toxicol Suppl       Date:  1984

7.  Prostaglandin generation from gastroduodenal mucosa: regional and species differences.

Authors:  D A Ahlquist; J A Duenes; T H Madson; J C Romero; R R Dozois; J R Malagelada
Journal:  Prostaglandins       Date:  1982-07

8.  Gastric mucosal prostaglandin E levels in patients with gastric ulcer disease and carcinoma.

Authors:  J P Wright; G O Young; L J Klaff; L A Weers; S K Price; I N Marks
Journal:  Gastroenterology       Date:  1982-02       Impact factor: 22.682

9.  Duodenal prostaglandin synthesis and acid load in health and in duodenal ulcer disease.

Authors:  D A Ahlquist; R R Dozois; A R Zinsmeister; J R Malagelada
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

10.  Dysfunctions of the stomach with gastric ulceration.

Authors:  L J Miller; J R Malagelada; G F Longstreth; V L Go
Journal:  Dig Dis Sci       Date:  1980-11       Impact factor: 3.199

View more
  4 in total

Review 1.  Peptic ulcer--an infectious disease?

Authors:  W L Peterson
Journal:  West J Med       Date:  1990-02

2.  Mucosal prostaglandin levels of the gastric stump.

Authors:  I Dobó; K Tihanyi; J Banai; I Szántó; I Rózsa
Journal:  Gastroenterol Jpn       Date:  1988-10

Review 3.  Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

Authors:  J P Monk; S P Clissold
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

4.  Association of Vagotomy and Decreased Risk of Subsequent Ischemic Stroke in Complicated Peptic Ulcer Patients: an Asian Population Study.

Authors:  Chu-Wen Fang; Chun-Hung Tseng; Shih-Chi Wu; William Tzu-Liang Chen; Chih-Hsin Muo
Journal:  World J Surg       Date:  2017-12       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.